Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MRVI Stock Forecast 2025-2026
$3.70
Current Price
$1.36B
Market Cap
Buy 5
Hold 6
Sell 0
Wall St Analyst Ratings
Distance to MRVI Price Targets
+35.1%
To High Target of $5.00
+8.1%
To Median Target of $4.00
-45.9%
To Low Target of $2.00
MRVI Price Momentum
+2.2%
1 Week Change
+28.9%
1 Month Change
-26.7%
1 Year Change
-32.1%
Year-to-Date Change
-40.4%
From 52W High of $6.21
+122.2%
From 52W Low of $1.67
📊 TOP ANALYST CALLS
Did MRVI Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Maravai is one of their latest high-conviction picks.
Latest MRVI Stock Price Targets & Analyst Predictions
Based on our analysis of 17 Wall Street analysts, MRVI has a neutral consensus with a median price target of $4.00 (ranging from $2.00 to $5.00). The overall analyst rating is N/A (N/A/10). Currently trading at $3.70, the median forecast implies a 8.1% upside. This outlook is supported by 5 Buy, 6 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Christian Schwab at Craig-Hallum, projecting a 35.1% upside. Conversely, the most conservative target is provided by Catherine Schulte at Baird, suggesting a 45.9% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MRVI Analyst Ratings
5
Buy
6
Hold
0
Sell
MRVI Price Target Range
Low
$2.00
Average
$4.00
High
$5.00
Current: $3.70
Latest MRVI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MRVI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 12, 2025 | Craig-Hallum | Christian Schwab | Buy | Maintains | $5.00 |
| Aug 12, 2025 | RBC Capital | Conor McNamara | Outperform | Maintains | $5.00 |
| May 13, 2025 | Baird | Catherine Schulte | Neutral | Maintains | $2.00 |
| May 13, 2025 | Craig-Hallum | Christian Schwab | Buy | Maintains | $10.00 |
| Mar 25, 2025 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $5.00 |
| Mar 21, 2025 | UBS | Dan Brennan | Neutral | Maintains | $2.50 |
| Mar 3, 2025 | B of A Securities | Michael Ryskin | Buy | Maintains | $8.00 |
| Feb 26, 2025 | Baird | Catherine Schulte | Neutral | Downgrade | $3.00 |
| Dec 5, 2024 | Goldman Sachs | Matthew Sykes | Sell | Downgrade | $4.25 |
| Nov 14, 2024 | Wolfe Research | Doug Schenkel | Peer Perform | Initiates | $N/A |
| Nov 8, 2024 | William Blair | Matt Larew | Market Perform | Downgrade | $N/A |
| Nov 8, 2024 | RBC Capital | Conor McNamara | Outperform | Maintains | $13.00 |
| Nov 8, 2024 | Baird | Catherine Schulte | Outperform | Maintains | $9.00 |
| Oct 8, 2024 | Goldman Sachs | Matthew Sykes | Neutral | Maintains | $7.00 |
| Aug 27, 2024 | Wells Fargo | Brandon Couillard | Overweight | Initiates | $10.00 |
| Aug 16, 2024 | RBC Capital | Conor McNamara | Outperform | Reiterates | $15.00 |
| Aug 13, 2024 | Morgan Stanley | Tejas Savant | Equal-Weight | Downgrade | $10.00 |
| Aug 8, 2024 | Goldman Sachs | Matthew Sykes | Neutral | Maintains | $8.00 |
| Aug 8, 2024 | UBS | Dan Brennan | Neutral | Maintains | $11.00 |
| Jul 9, 2024 | Goldman Sachs | Matthew Sykes | Neutral | Maintains | $7.00 |
Maravai Lifesciences Holdings Inc. (MRVI) Competitors
The following stocks are similar to Maravai based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Maravai Lifesciences Holdings Inc. (MRVI) Financial Data
Maravai Lifesciences Holdings Inc. has a market capitalization of $1.36B with a P/E ratio of 28.4x. The company generates $192.44M in trailing twelve-month revenue with a -62.9% profit margin.
Revenue growth is -39.7% quarter-over-quarter, while maintaining an operating margin of -80.7% and return on equity of -40.9%.
Valuation Metrics
Market Cap
$1.36B
Enterprise Value
$847.37M
P/E Ratio
28.4x
PEG Ratio
-0.4x
Price/Sales
7.0x
Growth & Margins
Revenue Growth (YoY)
-39.7%
Gross Margin
+13.6%
Operating Margin
-80.7%
Net Margin
-62.9%
EPS Growth
-36.2%
Financial Health
Cash/Price Ratio
+45.4%
Current Ratio
5.3x
Debt/Equity
85.2x
ROE
-40.9%
ROA
-7.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Maravai Lifesciences Holdings Inc. (MRVI) Business Model
About Maravai Lifesciences Holdings Inc.
What They Do
Provides critical products for biotechnology research.
Business Model
The company generates revenue by producing nucleic acids and biologics that are essential for drug development, diagnostics, and molecular testing. Their innovative solutions in mRNA technology support the biopharmaceutical industry, particularly in vaccine and therapeutic development.
Additional Information
Maravai Lifesciences plays a crucial role in enabling scientific research and innovation, catering to a global demand for advanced medical solutions. Their commitment to precision and support for healthcare institutions positions them as a key player in the life sciences market.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
550
CEO
Mr. Bernd Brust
Country
United States
IPO Year
2020
Website
www.maravai.comMaravai Lifesciences Holdings Inc. (MRVI) Latest News & Analysis
Latest News
Quick Summary
Maravai LifeSciences (NASDAQ: MRVI) CFO Raj Asarpota will speak at the Stifel Healthcare Conference on November 12, 2025, and another event on November 19, 2025.
Why It Matters
Maravai LifeSciences' participation in investor conferences signals potential insights into company strategy and performance, influencing investor sentiment and stock valuation.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Maravai LifeSciences Holdings, Inc. will hold its Q3 2025 earnings call on November 6, 2025, at 5:00 PM EST, featuring key executives and analysts from major financial institutions.
Why It Matters
The upcoming Q3 earnings call for Maravai LifeSciences may reveal key financial metrics and strategic insights, impacting stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Maravai LifeSciences reported Q3 2025 revenue of $41.6M, a net loss of $45.1M, and an Adjusted EBITDA of $(10.8)M. The company expresses confidence in future business prospects.
Why It Matters
Maravai's significant revenue drop and net loss could indicate financial instability, potentially affecting stock performance and investor confidence in future growth.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Maravai LifeSciences (MRVI) reported a quarterly loss of $0.08 per share, worse than the expected loss of $0.06, and compared to a loss of $0.02 per share a year ago.
Why It Matters
Maravai's larger-than-expected quarterly loss signals potential operational challenges, which could impact investor confidence and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Maravai's stock fell 22% after the company delayed its earnings report, allegedly due to misstated revenue and overstated goodwill linked to weak internal controls.
Why It Matters
Misstated revenue and overstated goodwill signal serious internal control issues, raising concerns about Maravai's financial health and transparency, leading to a significant stock decline.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Maravai LifeSciences (NASDAQ: MRVI) will report Q3 2025 results on November 6, 2025, after market close, followed by a conference call at 2:00 p.m. PT.
Why It Matters
Maravai's upcoming financial results announcement may influence stock performance, investor sentiment, and market positioning, reflecting the company's operational health and growth prospects.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About MRVI Stock
What is Maravai Lifesciences Holdings Inc.'s (MRVI) stock forecast for 2026?
Based on our analysis of 17 Wall Street analysts, Maravai Lifesciences Holdings Inc. (MRVI) has a median price target of $4.00. The highest price target is $5.00 and the lowest is $2.00.
Is MRVI stock a good investment in 2026?
According to current analyst ratings, MRVI has 5 Buy ratings, 6 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.70. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MRVI stock?
Wall Street analysts predict MRVI stock could reach $4.00 in the next 12 months. This represents a 8.1% increase from the current price of $3.70. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Maravai Lifesciences Holdings Inc.'s business model?
The company generates revenue by producing nucleic acids and biologics that are essential for drug development, diagnostics, and molecular testing. Their innovative solutions in mRNA technology support the biopharmaceutical industry, particularly in vaccine and therapeutic development.
What is the highest forecasted price for MRVI Maravai Lifesciences Holdings Inc.?
The highest price target for MRVI is $5.00 from Christian Schwab at Craig-Hallum, which represents a 35.1% increase from the current price of $3.70.
What is the lowest forecasted price for MRVI Maravai Lifesciences Holdings Inc.?
The lowest price target for MRVI is $2.00 from Catherine Schulte at Baird, which represents a -45.9% decrease from the current price of $3.70.
What is the overall MRVI consensus from analysts for Maravai Lifesciences Holdings Inc.?
The overall analyst consensus for MRVI is neutral. Out of 17 Wall Street analysts, 5 rate it as Buy, 6 as Hold, and 0 as Sell, with a median price target of $4.00.
How accurate are MRVI stock price projections?
Stock price projections, including those for Maravai Lifesciences Holdings Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 6:15 PM UTC